Drug approval : entrectinib and larotrectinib - cancers with NTRK fusion

被引：2
|
作者：
Delaye, Matthieu [1 ,2 ]
Rodrigues, Manuel [3 ,4 ]
机构：
[1] Hop Tenon, Serv Oncol Med & Therapie Cellulaire, 4 Rue Chine, F-75020 Paris, France
[2] Assoc Enseignement & Rech Internes Oncol AERIO, 149 Ave Maine, F-75014 Paris, France
[3] PSL Res Univ, Inst Curie, Dept Oncol Med, 26 Rue Ulm, F-75005 Paris, France
[4] PSL Res Univ, Inst Curie, INSERM, U830, 26 Rue Ulm, F-75005 Paris, France
来源：
BULLETIN DU CANCER | 2020年 / 107卷 / 11期
关键词：
POSITIVE SOLID TUMORS;
D O I：
10.1016/j.bulcan.2020.09.009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1085 / +
页数：2
相关论文
共 50 条
  • [41] Entrectinib: First Global Approval
    Al-Salama, Zaina T.
    Keam, Susan J.
    DRUGS, 2019, 79 (13) : 1477 - 1483
  • [42] A novel EML4-NTRK3 fusion in lung adenocarcinoma with dramatic response to entrectinib
    Batra, Ullas
    Nathany, Shrinidhi
    Sharma, Mansi
    Jain, Parveen
    Mehta, Anurag
    Bansal, Abhishek
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (07) : 2045 - 2047
  • [43] A Unique Case Report of Infantil Gliomasarcoma with PTR-NTRK1 Fusion Treated with Larotrectinib
    Mancano, B.
    Reis, R.
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S506 - S507
  • [44] SUCCESSFUL TREATMENT OF AN NTRK-FUSION POSITIVE INFANTILE GLIOBLASTOMA WITH LAROTRECTINIB, A TARGETED TRK INHIBITOR
    Buerki, Robin
    Banerjee, Anuradha
    Zamorski, Alexandra
    Cox, Michael
    Raber, Shannon
    Solomon, David
    Mueller, Sabine
    NEURO-ONCOLOGY, 2019, 21 : 89 - 90
  • [45] Larotrectinib in NTRK-Rearranged Solid Tumors
    Wilson, Frederick H.
    Herbst, Roy S.
    BIOCHEMISTRY, 2019, 58 (12) : 1555 - 1557
  • [46] Larotrectinib followed by selitrectinib in a novelDCTN1-NTRK1fusion undifferentiated pleomorphic sarcoma
    Goh, Xue Na
    Seng, Michaela Su-Fern
    Loh, Amos Hong Pheng
    Gupta, Achint
    Chang, Kenneth Tou En
    Iyer, Prasad
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (02) : 485 - 489
  • [47] Larotrectinib in NTRK Fusion-Positive High-Grade Glioneuronal Tumor: A Case Report
    Tadipatri, Ramya
    Eschbacher, Jennifer
    Fonkem, Ekokobe
    Kresl, John
    Azadi, Amir
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (11)
  • [48] Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
    Drilon, A.
    Laetsch, T. W.
    Kummar, S.
    DuBois, S. G.
    Lassen, U. N.
    Demetri, G. D.
    Nathenson, M.
    Doebele, R. C.
    Farago, A. F.
    Pappo, A. S.
    Turpin, B.
    Dowlati, A.
    Brose, M. S.
    Mascarenhas, L.
    Federman, N.
    Berlin, J.
    El-Deiry, W. S.
    Baik, C.
    Deeken, J.
    Boni, V.
    Nagasubramanian, R.
    Taylor, M.
    Rudzinski, E. R.
    Meric-Bernstam, F.
    Sohal, D. P. S.
    Ma, P. C.
    Raez, L. E.
    Hechtman, J. F.
    Benayed, R.
    Ladanyi, M.
    Tuch, B. B.
    Ebata, K.
    Cruickshank, S.
    Ku, N. C.
    Cox, M. C.
    Hawkins, D. S.
    Hong, D. S.
    Hyman, D. M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (08): : 731 - 739
  • [49] The challenge of drug approval in rare cancers
    Kasper, Bernd
    CANCER, 2021, 127 (06) : 837 - 839
  • [50] Bayer applies for Approval for Larotrectinib for the Treatment of TRK-Fusion Tumors in the European Union
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 (10) : 658 - 658
12345